Table 3.
Clinical remission according to treatment group in patients with oligoarticular JIA
| SDMARD alone n = 66 |
SDMARD combined n = 18 |
SDMARD BDMARD combined n = 25 |
BDMARD alone n = 3 |
Clinical remission n = 112 |
p | |
|---|---|---|---|---|---|---|
| Persistent | 61 (92) | 13 (72) | 17 (68) | 1 (33) | 92 (46) | 0.003 |
| Comorbidities b absence, n (%) | 58 (88) | 15 (83) | 23 (92) | 1 (33) | 97 (87) | 0.042 |
| Synthetic DMARD a, n (%) | ||||||
| Metotrexate | 53 (80) | 9 (50) | 8 (50) | 0 | 70 (35) | 0.025 |
| First DMARD course c, n (%) | 44 (67) | 6 (28) | 11 (44) | 0 | 60 (54) | 0.014 |
| DMARD dose tapering a, n (%) | 51 (77) | 8 (44) | 15 (60) | 3 (100) | 77 (69) | 0.024 |
SDMARD Synthetic disease modifying drug, BDMARD Biologic disease modifying drug, JIA Juvenile idiopathic arthritis, n Number;
ap < 0,05 Statistically significant differences using the χ2 test
bComorbidities other than uveitis and not related to drug toxicity
cFirst DMARD course = DMARD dispensed in the first place, chronologically